When Is a Placebo Effect Not an Effect?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Homeopathy and Psychological Therapies
Entry Homeopathy and Psychological Therapies Davide Donelli * and Michele Antonelli AUSL-IRCCS Reggio Emilia, 42122 Reggio Emilia, Italy; [email protected] * Correspondence: [email protected] Definition: Homeopathy is a popular, although highly debated, medicinal practice based on the administration of remedies in which active substances are so diluted that no detectable trace of them remains in the final product. This hypothesis paper aims to outline a possible reinterpreta- tion of homeopathy in the light of psychological therapies in order to improve its clinical safety and sustainability. Keywords: homeopathy; psychology; reinterpretation; hypothesis 1. Introduction Homeopathy is a popular, although highly debated, medicinal practice. In Italy, for ex- ample, it is estimated that, even if with a slightly declining trend, around 4.1% of the entire population (almost 2.5 million people) occasionally or regularly seeks homeopathic care, and these data, collected in 2013, suggest that homeopathy is the most used Complemen- tary and Alternative Medicine (CAM) by Italians [1]. Epidemiological studies aimed to assess the worldwide prevalence of homeopathy use have reported similar data for other high-income countries [2]. Homeopathy was first invented by the German doctor Samuel Hahnemann (1755–1843), and it is based on the administration of remedies in which active substances are so diluted that no detectable trace of them remains in the final product [3]. In his empirical studies, Citation: Donelli, D.; Antonelli, M. Hahnemann reported that the self-administration of a common antimalarial medicinal Homeopathy and Psychological Ther- plant (Cinchona) resulted in the occurrence of the same symptoms of malaria, but to a Encyclopedia 2021 1 apies. -
Ocps) Used in the NM Family Planning Program (FPP
The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations. -
Nicotine and Behavioral Markers of Risk for Schizophrenia: a Double-Blind, Placebo- Controlled, Cross-Over Study Lana Dépatie, M.Sc., Gillian A
Nicotine and Behavioral Markers of Risk for Schizophrenia: A Double-Blind, Placebo- Controlled, Cross-Over Study Lana Dépatie, M.Sc., Gillian A. O’Driscoll, Ph.D., Anne-Lise V. Holahan, B.Sc., Victoria Atkinson, R.N., Joseph X. Thavundayil, M.D., N. Ng Ying Kin, Ph.D., and Samarthji Lal, M.D. We investigated the effect of nicotine on three behavioral groups. A Drug ϫ Monitoring condition interaction (p Ͻ .01) markers of risk for schizophrenia: sustained attention on pursuit gain indicated that nicotine significantly (using the Continuous Performance Task (CPT)), increased pursuit gain in the no-monitoring condition in antisaccade performance, and smooth pursuit. Smooth patients and controls equally, but did not improve pursuit pursuit was investigated in two conditions, one in which in the monitoring condition. Thus, improvement in pursuit attention was enhanced (monitoring target changes) and may have been mediated via an effect on attention rather one in which attention was not enhanced (no monitoring). than by an effect on oculomotor function per se. In patients, Patients with schizophrenia (n ϭ 15) and controls (n ϭ 14) the magnitude of improvement in attention on nicotine was were given a 14-mg nicotine patch in a double-blind, correlated with the improvement on eye movement tasks. placebo-controlled, crossover design and plasma nicotine Thus, nicotine improves performance on both attention and concentrations were monitored. Nicotine concentrations oculomotor markers of risk for schizophrenia, possibly via were similar in both groups. A Group ϫ Drug interaction common mechanisms. (p Ͻ .02) on CPT hits indicated that nicotine improved [Neuropsychopharmacology 27:1056–1070, 2002] sustained attention in patients but not in controls. -
The Placebo and Nocebo Effect on Sports Performance: a Systematic Review
The Placebo and Nocebo Effect on Sports Performance: A Systematic Review Philip Hursta*, Lieke Schipof-Godartb, Attila Szaboc, John Raglind, Florentina Hettingae, Bart Roelandsf, Andrew Laneg, Abby Foada, Damian Colemana & Chris Beedieh aSchool of Human and Life Sciences, Canterbury Christ Church University, Canterbury, UK bFaculty of Health, Nutrition & Sports, The Hague University of Applied Sciences, Hague, the Netherlands cInstitute of Health Promotion and Sports Sciences, Eötvös Loránd University, Budapest, Hungary dSchool of Public Health, Indiana University, Bloomington, IN, USA eSchool of Sport, Rehabilitation and Exercise Sciences, University of Essex, Colchester, UK fDepartment of Human Physiology, Vrije Universiteit Brussel, Brussels, Belgium gFaculty of Education Health and Wellbeing, Institute of Sport, University of Wolverhampton, Walsall, UK hSchool of Psychology, University of Kent, Canterbury, UK *Correspondence: Philip Hurst, School of Human and Life Sciences, Canterbury Christ Church University, Canterbury, UK. Email: [email protected] # Name Email address 1 Dr Philip Hurst [email protected] 2 Dr Lieke Schipof-Godart [email protected] 3 Professor Attila Szabo [email protected] 4 Professor John Raglin [email protected] 5 Professor Florentina Hettinga [email protected] 6 Dr Bart Roelands [email protected] 7 Professor Andrew Lane [email protected] 8 Dr Abby Foad [email protected] 9 Dr Damian Coleman [email protected] 10 Professor Chris Beedie [email protected] 1 Abstract The aim of this review was to determine the magnitude of the placebo and nocebo effect on sport performance. Articles published before March 2019 were located using Medline, Web of Science, PubMed, EBSCO, Science Direct, and Scopus. -
The Nocebo Effect in Current Practice
First Five Years College The nocebo effect in current practice Kalpit Agnihotri MD CCFP ACBOM n 2013, the European Journal of Neurology published seriously ill and extremely weak. From the missionary a meta-analysis examining patient dropout rates he learned that Rob had had a bone pointed at him owing to medication side effects in clinical trials for by Nebo and was convinced that in consequence he IParkinson disease treatments.1 A review of more than a must die. Thereupon Dr. Lambert and the missionary decade of various trials showed that nearly two-thirds went for Nebo, threatened him sharply that his sup- of patients reported an adverse event after drug therapy. ply of food would be shut off if anything happened to Worse still, nearly one-tenth (8.8%) of the patients in a Rob …. At once Nebo agreed to go with them to see specific arm of the studies experienced such horrific side Rob. He leaned over Rob’s bed and told the sick man effects that they were forced to stop treatment altogether. that it was all a mistake, a mere joke—indeed, that Strangely, this subset of patients had not been given any he had not pointed a bone at him at all. The relief, active medication at all—they had been given a placebo. Dr. Lambert testifies, was almost instantaneous; that The placebo arm of a research study is crucial to the evening Rob was back at work, quite happy again, modern scientific method and is used to better under- and in full possession of his physical strength.3 stand the medication and confirm that it gives a true result beyond subjective experience. -
Demystifying the Placebo Effect
City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 9-2018 Demystifying the Placebo Effect Phoebe Friesen The Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/2775 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] DEMYSTIFYING THE PLACEBO EFFECT by PHOEBE FRIESEN A dissertation submitted to the Graduate Faculty in Philosophy in partial fulfillment of the requirements for the degree of Doctor of Philosophy, The City University of New York 2018 © 2018 PHOEBE FRIESEN All Rights Reserved ii Demystifying the Placebo Effect by Phoebe Friesen This manuscript has been read and accepted for the Graduate Faculty in Philosophy in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy. ___________ ____________________________________ Date [Peter Godfrey-Smith] Chair of Examining Committee ___________ ____________________________________ Date [Nickolas Pappas ] Executive Office Supervisory Committee: Peter Godfrey-Smith Jesse Prinz John Greenwood THE CITY UNIVERSITY OF NEW YORK iii ABSTRACT Demystifying the Placebo Effect by Phoebe Friesen Advisor: Peter Godfrey-Smith This dissertation offers a philosophical analysis of the placebo effect. After offering an overview of recent evidence concerning the phenomenon, I consider several prominent accounts of the placebo effect that have been put forward and argue that none of them are able to adequately account for the diverse instantiations of the phenomenon. I then offer a novel account, which suggests that we ought to think of the placebo effect as encompassing three distinct responses: conditioned placebo responses, cognitive placebo responses, and network placebo responses. -
Placebo-Controlled Trials of New Drugs: Ethical Considerations
Reviews/Commentaries/Position Statements COMMENTARY Placebo-Controlled Trials of New Drugs: Ethical Considerations DAVID ORENTLICHER, MD, JD als, placebo controls are not appropriate when patients’ health would be placed at significant risk (8–10). A placebo- controlled study for a new hair- uch controversy exists regarding sufficiently more effective than placebo to thickening agent could be justified; a the ethics of placebo-controlled justify its use. Finally, not all established placebo-controlled study for patients M trials in which an experimental therapies have been shown to be superior with moderate or severe hypertension therapy will compete with an already es- to placebo. If newer drugs are compared would not be acceptable (11). Similarly, if tablished treatment (or treatments). In with the unproven existing therapies, an illness causes problems when it goes such cases, argue critics, patients in the then patients may continue to receive untreated for a long period of time, a 52- control arm of the study should receive an drugs that are harmful without being week study with a placebo control is accepted therapy rather than a placebo. helpful. much more difficult to justify than a By using an active and effective drug, the Moreover, say proponents of placebo 6-week study (12). control patients would not be placed at controls, patients can be protected from When David S.H. Bell (13) explains risk for deterioration of their disease, and harm by “escape” criteria, which call for why placebo controls are unacceptable the study would generate more meaning- withdrawal from the trial if the patient for new drugs to treat type 2 diabetes, he ful results for physicians. -
It Is Not Just the Drugs That Matter: the Nocebo Effect
Cancer and Metastasis Reviews (2019) 38:315–326 https://doi.org/10.1007/s10555-019-09800-w CLINICAL It is not just the drugs that matter: the nocebo effect Marek Z. Wojtukiewicz1,2 & Barbara Politynska3,4 & Piotr Skalij1,2 & Piotr Tokajuk1,2 & Anna M. Wojtukiewicz3 & Kenneth V. Honn5,6,7 Published online: 16 June 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The role of psychological mechanisms in the treatment process cannot be underestimated, the well-known placebo effect unquestionably being a factor in treatment. However, there is also a dark side to the impact of mental processes on health/ illness as exemplified by the nocebo effect. This phenomenon includes the emergence or exacerbation of negative symptoms associated with the therapy, but arising as a result of the patient’s expectations, rather than being an actual complication of treatment. The exact biological mechanisms of this process are not known, but cholecystokinergic and dopaminergic systems, changes in the HPA axis, and the endogenous secretion of opioids are thought to be involved. The nocebo effect can affect a significant proportion of people undergoing treatment, including cancer patients, leading in some cases to the cessation of potentially effective therapy, because of adverse effects that are not actually part of the biological effect of treatment. In extreme cases, as a result of suggestions and expectations, a paradoxical effect, biologically opposite to the mechanism of the action of the drug, may occur. In addition, the nocebo effect may significantly interfere with the results of clinical trials, being the cause of a significant proportion of complications reported. -
Homeopathy Is Marketed As a Safe, Natural and Holistic Treatment for a Range of Ailments and Illnesses, Including Another Way of Saying
sense about... sense about... sense about... sense about... sense about... sense about...Homeo sense about... sense about...path sense about...yyy sense about... sense about... sense about... sense about... sense about... sense about... sense about... Homeopathy is marketed as a safe, natural and holistic treatment for a range of ailments and illnesses, including Another way of saying... arthritis, asthma, depression, eczema, diarrhoea, hayfever, 8lacebo 999 a prescription that is inert; that is, it does nothing, headaches, insomnia and toothache. Homeopathic products and like a sugar pill or water. From the Latin, 1 will please.) services have become a large industry. 8lacebo effect 9 an effect, biological, biochemical or Despite this, it has not been embraced by medical science. The physiological, that emerges from an inert treatment because scientific evidence shows that homeopathy acts only as a the patient believes it will work. See page 2 for how placebos work.) placebo and there is no scientific explanation of how it could work any other way. Not to be confused... HomeoHomeopathpathpathicic principles 8roven 999 0proving( is the method homeopaths use to determine the symptoms a substance causes with a view to Homeopathy is based on two beliefs: 1) like cures like; and 2) treating diseases with similar symptoms); after the process a the smaller the dose the more potent the cure. First, homeopaths substance is said to be 0proven(. Scientists use 0proven( to choose a substance that causes the same symptoms as the describe a statement that is, by logic, necessarily true. disease they want to treat. For example, the runny nose and watery eyes of a cold can be recreated by inhaling onion fumes, human and animal waste, dead plants, bacteria and minerals; it so onion juice can form the basis of a homeopathic preparation. -
Nocebo Effects Can Make You Feel Pain Negative Expectancies Derived from Features of Commercial Drugs Elicit Nocebo Effects
INSIGHTS | PERSPECTIVES NEUROSCIENCE Nocebo effects can make you feel pain Negative expectancies derived from features of commercial drugs elicit nocebo effects By Luana Colloca ferential nocebo effects between the expen- administration was interrupted (13). These sive and cheaper treatments. Expectancies findings provide evidence that communica- he mysterious phenomenon known of higher pain-related side effects associated tion of treatment discontinuation might, at as the nocebo effect describes nega- with the expensive cream may have triggered least in part, lead to nocebo effects with ag- tive expectancies. This is in contrast to a facilitation of nociception processes at early gravation of symptoms. positive expectancies that trigger pla- subcortical areas and the spinal cord [which In placebo-controlled clinical trials, no- cebo effects (1). In evolutionary terms, are also involved in placebo-induced reduc- cebo effects can influence patients’ clinical nocebo and placebo effects coexist to tion of pain (8)]. The rACC showed a deac- outcomes and treatment adherence. It was Tfavor perceptual mechanisms that anticipate tivation and favored a subsequent activation shown in a clinical trial that atorvastatin in- threat and dangerous events (nocebo effects) of the PAG and spinal cord, resulting in an duced in the same individuals an excess rate and promote appetitive and safety behaviors increase of the nociceptive inputs. This sug- of muscle-related adverse events in the non- (placebo effects). In randomized placebo- gests that the rACC–PAG–spinal cord axis blinded (i.e., patients knew they were taking Downloaded from controlled clinical trials, patients that re- may orchestrate the effects of pricing on no- atorvastatin), nonrandomized 3-year follow- ceive placebos often report cebo hyperalgesia. -
A Functional Magnetic Resonance Imaging Study on the Neural Mechanisms of Hyperalgesic Nocebo Effect
13354 • The Journal of Neuroscience, December 3, 2008 • 28(49):13354–13362 Behavioral/Systems/Cognitive A Functional Magnetic Resonance Imaging Study on the Neural Mechanisms of Hyperalgesic Nocebo Effect Jian Kong,1,2 Randy L. Gollub,1,2,3 Ginger Polich,1 Irving Kirsch,4 Peter LaViolette,1,2 Mark Vangel,2,3 Bruce Rosen,2 and Ted J. Kaptchuk5 1Department of Psychiatry, Massachusetts General Hospital, 2Massachusetts General Hospital/Massachusetts Institute of Technology/Harvard Medical School Athinoula A. Martinos Center for Biomedical Imaging, and 3Massachusetts General Hospital Clinical Research Center Biomedical Imaging Core, Charlestown, Massachusetts 02129, 4Department of Psychology, University of Hull, Hull HU6 7RX, United Kingdom, and 5Osher Institute, Harvard Medical School, Boston, Massachusetts 02215 Previous studies suggest that nocebo effects, sometimes termed “negative placebo effects,” can contribute appreciably to a variety of medical symptoms and adverse events in clinical trials and medical care. In this study, using a within-subject design, we combined functional magnetic resonance imaging (fMRI) and an expectation/conditioning manipulation model to investigate the neural substrates of nocebo hyperalgesia using heat pain on the right forearm. Thirteen subjects completed the study. Results showed that, after adminis- tering inert treatment, subjective pain intensity ratings increased significantly more on nocebo regions compared with the control regions in which no expectancy/conditioning manipulation was performed. fMRI analysis of hyperalgesic nocebo responses to identical calibrated noxious stimuli showed signal increases in brain regions including bilateral dorsal anterior cingulate cortex (ACC), insula, superior temporal gyrus; left frontal and parietal operculum, medial frontal gyrus, orbital prefrontal cortex, superior parietal lobule, and hippocampus; right claustrum/putamen, lateral prefrontal gyrus, and middle temporal gyrus. -
Placebo As a Treatment for Depression Walter A
NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.4 265 REVIEW AND COMMENTARIES Placebo as a Treatment for Depression Walter A. Brown, M.D. The placebo response rate in depression consistently falls the psychotherapies (expectation of improvement, between 30 and 40%. Among more severely depressed support, mobilization of hope) are provided with pill patients antidepressants offer a clear advantage over placebo treatment. placebo; among less severely depressed patients and those The placebo response in depression has been viewed with a relatively short episode duration the placebo as a nuisance rather than as a therapeutic and research response rate is close to 50% and often indistinguishable opportunity. I propose that the initial treatment for from the response rate to antidepressants. In the selected depressed patients should be four to six weeks of treatment of depression none of the psychotherapies have placebo. Patients so treated should be informed that the consistently been shown to offer an advantage over pill placebo pill contains no drug but that this treatment can placebo. This is not entirely surprising given the fact that be helpful. [Neuropsychopharmacology 10:265-269, the common, and arguably the therapeutic, features of 1994J 1992; 1991). KEY WORDS: Placebo; Depression; Psychotherapy; C. Beasley, personal communication [One Antidepressant explanation for this apparent increase in the placebo response is that the relative paucity of side effects with I am proposing that the initial treatment for a sizable the newer drugs makes the results of placebo-controlled portion of depressed patients should be four to six studies less biased by knowledge of which patients are weeks of placebo.